Ocular Research Development from 2010 to 2026

OCUL Stock  USD 10.28  0.57  5.25%   
Ocular Therapeutix Research Development yearly trend continues to be quite stable with very little volatility. Research Development may rise above about 154.1 M this year. From the period between 2010 and 2026, Ocular Therapeutix, Research Development regression line of its data series had standard deviation of  47,088,036 and standard deviation of  47,088,036. View All Fundamentals
 
Research Development  
First Reported
2012-12-31
Previous Quarter
51.1 M
Current Value
52.4 M
Quarterly Volatility
11.7 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Ocular Therapeutix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocular Therapeutix's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.6 M, Interest Expense of 16.4 M or Selling General Administrative of 73.2 M, as well as many indicators such as Price To Sales Ratio of 23.17, Dividend Yield of 0.0 or PTB Ratio of 4.05. Ocular financial statements analysis is a perfect complement when working with Ocular Therapeutix Valuation or Volatility modules.
  
Build AI portfolio with Ocular Stock
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Latest Ocular Therapeutix's Research Development Growth Pattern

Below is the plot of the Research Development of Ocular Therapeutix over the last few years. It is Ocular Therapeutix's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ocular Therapeutix's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Ocular Research Development Regression Statistics

Arithmetic Mean49,906,324
Geometric Mean34,506,659
Coefficient Of Variation94.35
Mean Deviation34,552,537
Median30,880,000
Standard Deviation47,088,036
Sample Variance2217.3T
Range143.6M
R-Value0.86
Mean Square Error629.9T
R-Squared0.73
Significance0.000011
Slope7,987,228
Total Sum of Squares35476.5T

Ocular Research Development History

2026154.1 M
2025146.8 M
2024127.6 M
202361.1 M
202253.5 M
202150.1 M
202028.7 M

About Ocular Therapeutix Financial Statements

Ocular Therapeutix investors utilize fundamental indicators, such as Research Development, to predict how Ocular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development146.8 M154.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. Anticipated expansion of Ocular directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ocular Therapeutix assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.43)
Revenue Per Share
0.321
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.37)
Return On Equity
(0.82)
Ocular Therapeutix's market price often diverges from its book value, the accounting figure shown on Ocular's balance sheet. Smart investors calculate Ocular Therapeutix's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Ocular Therapeutix's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Ocular Therapeutix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ocular Therapeutix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.